Sanofi studies potential acquisitions of US biotechnology companies including Principia Biopharma
Chief Executive Officer Paul Hudson, who joined last year, is seeking to rejuvenate Sanofi by focusing on fast-growing areas where new medicines command high prices. There's no certainty the deliberations will lead to a transaction, according to the people.;
Paris: Sanofi is studying potential acquisitions of U.S. biotechnology companies including Principia Biopharma Inc. as it seeks innovative treatments for clinical areas including multiple sclerosis and immune disorders, people with knowledge of the matter said.
The French drugmaker is working with advisers to study potential deals, the people said, asking not to be identified because the information is private.
Chief Executive Officer Paul Hudson, who joined last year, is seeking to rejuvenate Sanofi by focusing on fast-growing areas where new medicines command high prices. There's no certainty the deliberations will lead to a transaction, according to the people.
Sanofi shares were little changed early Friday in Paris.
Sanofi already has a partnership with Principia Biopharma to develop a treatment for central nervous system diseases. Principia Biopharma rallied in February after the experimental medicine succeeded in a mid-stage study and Sanofi's CEO said it could grab half of the $20 billion markets for multiple sclerosis drugs.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.